Does insurance cover semaglutide?
There is no one answer. A plan does not cover “semaglutide” — it covers named products, for named medical reasons, at a position on its own drug list. The question with an answer is whether your plan covers the product on your prescription, for the reason it was written.
On this page
- The four things a plan is deciding
- Why the product matters more than the molecule
- How to find out, for your plan
- If you are on a Medicare drug plan
- If your plan is through work or the Marketplace
- Compounded semaglutide is a different question
- What this page will not do
- Questions
- If a plan will not cover it
- If a telehealth program offers insurance support
- When to call your prescriber
The four things a plan is deciding
Anyone who answers the headline question with a flat yes or no is guessing, because the answer is assembled from four separate decisions. They are made in this order, and a “no” at any one of them looks identical from the outside — which is why “my insurance said no” is not yet enough information to act on.
| What it is called | What it decides |
|---|---|
| The product | Whether this exact product, not the molecule, is on the plan’s drug list. Two products can contain semaglutide and sit in completely different places on a formulary. |
| The indication | The medical reason the prescription was written for. Medicare’s own guidance says plans may use prior authorization “when they only cover a drug for certain medical conditions, but not others.” |
| The formulary tier | Where on the drug list it sits, which sets what you pay rather than whether you are covered at all. A drug can be covered and still cost more than you expected. |
| The utilization rules | Prior authorization, step therapy and quantity limits. These are conditions on a covered drug, not a refusal — what prior authorization actually is covers them. |
The names in the first column are the plan’s own vocabulary — use them when you call. The prior-authorization description is Medicare’s own, from Medicare.gov “Drug plan rules”, read September 2026; that page prints no revision date, and it is listed under Sources below.
Why the product matters more than the molecule
The same active ingredient is sold as different products approved for different medical reasons, and a drug list is a list of products. Here is what two of the labels themselves say, which is the level of detail a plan is working at:2,3
| Product | What the label says it is indicated for |
|---|---|
| WEGOVY injection | With a reduced calorie diet and increased physical activity: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; reducing excess body weight and maintaining weight reduction long term in adults and pediatric patients aged 12 and over with obesity, and in adults with overweight plus at least one weight-related comorbid condition; and treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults — an indication the label states is approved under accelerated approval, based on improvement of MASH and fibrosis. |
| WEGOVY tablets | With a reduced calorie diet and increased physical activity: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; and reducing excess body weight and maintaining weight reduction long term in adults with obesity, or in adults with overweight plus at least one weight-related comorbid condition. The same label carries both forms, and the tablets do not share the injection’s pediatric or MASH indications. |
| OZEMPIC | As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. |
Indications as printed in each product’s own current prescribing information on DailyMed: WEGOVY label revised 6/2026, OZEMPIC label revised 5/2026; both listed under Sources below. Abridged — read the label itself for the full text, and note that a label can be revised at any time.
This is not a complete list of semaglutide products and it is not a claim about what any plan does with any of them. It is here to make one point: if you ask a plan about “semaglutide” you will get a vague answer, and if you ask about a product name and a strength you will get a specific one.
How to find out, for your plan
In this order. Steps one and two are free, take about twenty minutes, and settle most of it before you speak to anybody.
- Read the prescription, not your memory of it. Write down the exact product name, the strength, and the quantity. “Semaglutide” on its own is not enough to look anything up.
- Find your plan’s drug list. It is usually called a formulary or a “list of covered drugs,” and it is normally in the member portal or the plan documents. Search it for the product name you just wrote down.
- Read what the entry says beside the name. A tier number, and any flags for prior authorization, step therapy or a quantity limit. Those flags are the whole story: they tell you whether the answer is “no” or “yes, once your prescriber sends us something.”
- Call the member services number on your card and ask three specific questions: is this product covered for this diagnosis, what does it require before it is covered, and what is my cost at that tier. Write down the date, the name of the person, and the reference number for the call.
- Ask the prescriber’s office to run a benefits check and, if the drug needs it, to submit the prior authorization. This is routine work for a prescriber’s office and it is not something you can file yourself.
- Get any refusal in writing. You cannot appeal a phone call. The written notice is what starts every clock described on the prior authorization page.
If you are on a Medicare drug plan
Since the summer of 2026 there are two doors, not one. The first is a program that sits outside your drug plan’s formulary altogether, and CMS’s fact sheet — which carries June 2026 on its own face — opens with it:
Starting July 1, 2026, Medicare has a new program called Medicare GLP-1 Bridge to help you pay for certain GLP-1 weight loss medicines.
It names three products — Foundayo tablets, WEGOVY in either form, and the Zepbound KwikPen — and charges $50 a month for them whatever you earn. It is only for people who are not already able to get a GLP-1 through their own drug plan, and there are age and BMI requirements. Who qualifies, what the prescriber files and what the $50 does not buy you are set out on the page on WEGOVY and insurance.7
The second door is your drug plan itself, which is where an OZEMPIC prescription goes, and where a WEGOVY prescription goes if the Bridge is not open to you. That is the door the rest of this page describes.
Medicare’s own guidance describes prior authorization as approval “based on a plan’s specific requirements” that you or your prescriber must get before the plan covers certain drugs, and describes an exception as when a drug plan “decides to cover a drug that’s not on its drug list, or to waive a coverage rule.” It also describes a transition fill — a one-time 30-day supply of a drug you have been taking that your plan either does not cover or requires prior authorization or step therapy for.4
That transition fill is the part people miss, because it looks like the problem has gone away. It has not; it has bought you a month to get the paperwork done.
If your plan is through work or the Marketplace
HealthCare.gov lists the reasons a plan may issue a denial, and the ones that usually matter here are “the benefit isn’t offered under your health plan” and that the requested treatment is “not medically necessary.” Those two are different problems with different routes: the first is a question about what your employer or plan bought, the second is a question your prescriber can answer with clinical documentation.5
One of the grounds HealthCare.gov lists for a denial is simply that the benefit is not offered under your plan. If that is what has happened, an appeal arguing medical necessity is answering a question nobody asked, so the thing to establish first is whether the benefit exists in your plan at all.
The four levers in the first table are described above in Medicare’s vocabulary because that is where they are written down publicly. The documents that govern an employer or Marketplace plan are your own plan’s, so those are the ones to check the four against.
Compounded semaglutide is a different question
Treating these as one question can give you an answer that does not apply to the product you are actually taking. FDA states plainly that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness or quality before they are marketed. Why compounded semaglutide is a separate coverage question takes that apart.1
What this page will not do
What it can do is make sure you are asking the right question of the right document. The rest of the answer is in your plan’s own papers.
Questions
Does insurance cover semaglutide?
There is no one answer, and anyone giving you a flat yes or no is guessing. A plan covers named products for named medical reasons at a position on its own drug list. Write down the product name and strength from your prescription, then search your plan’s formulary for that name.
My plan covers OZEMPIC but not WEGOVY. How can that be?
Because a drug list is a list of products, not molecules, and those two products carry different indications on their own labels — see the table above. A plan can put them in completely different places, or exclude one outright as a benefit category.
They said no. What kind of no is it?
That is the question worth asking, and it is why you want the refusal in writing. HealthCare.gov lists both grounds: that the benefit is not offered under your plan, and that the plan does not consider the treatment medically necessary. If it is medical necessity, documentation is precisely what moves it — the prior authorization page covers the route and the deadlines.
What is a transition fill?
Medicare describes a one-time 30-day supply of a drug you have been taking that your plan either does not cover or requires prior authorization or step therapy for. It looks like the problem has gone away. It has not — it has bought you a month to get the paperwork done.4
If a plan will not cover it
The cash-pay picture is a separate page — what semaglutide costs by dose, not as one headline number.
If a telehealth program offers insurance support
Help with a prior authorization is a service, not a promise that your plan will pay. Before joining a program, ask whether its care fee is refundable if coverage is denied, whether medication is charged separately and who handles an appeal. The Mochi Health review separates membership from medication charges, a useful distinction when requesting a total.
The Ro review and Found review examine the difference between program fees and branded-medication costs. LifeMD’s review also separates its care fee from the medication bill. Use those service details alongside your plan’s own coverage decision; a program’s enrollment approval does not establish insurance eligibility.
When to call your prescriber
Call before you change or stop anything because of a coverage decision. A denial is a payment decision, not a clinical one, and stopping or stretching a dose to make a supply last is a decision that belongs with the person who wrote the prescription.
Coverage is three questions, not one, and each has its own page: what your plan is deciding is here, what your prescriber has to submit is on prior authorization and the appeal route, and whether a compounded prescription is treated differently is on is compounded semaglutide covered. If the answer turns out to be no, what the drug costs without a plan is on what semaglutide costs by dose, and what those figures include varies more than the figures themselves do.
Read next
Sources
A reference, not medical advice, and not a substitute for your prescriber or pharmacist. It is not insurance advice either: only your plan’s own documents and your plan’s own staff can tell you what it covers. If you think you are having a medical emergency, call your local emergency number.